spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche

Phoremost Ltd

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes


Cambridge, UK, 06 September 2022
: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, toward disease-relevant pathways nominated by Roche. Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.

The SITESEEKER® platform is based on PhoreMost’s core proprietary ‘Protein Interference’ (PROTEINi®) technology. PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. SITESEEKER® systematically unmasks new and unanticipated druggable sites across the entire human proteome, directly linking them to useful therapeutic functions.

Dr Neil Torbett, CEO of PhoreMost, said: “This collaboration with Roche is testament to the power and versatility of SITESEEKER, and further validates the potential and broad applications of the platform. We are delighted that Roche has chosen to work with us to enhance its drug discovery pipeline using PROTEINi and SITESEEKER to identify novel targets and unlock the power of protein structure prediction for next generation drug design.”
phone +44 (0)1223 804 163
email info@phoremost.com
web www.phoremost.com
email PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research


More info >>


White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement